These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 1408740)

  • 1. Long-term survival in remission of adult acute myeloid leukaemia (AML) patients.
    Ruvidic R; Boskovic D; Tomin D; Elezovic I
    Nouv Rev Fr Hematol (1978); 1992; 34(3):277. PubMed ID: 1408740
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
    Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
    Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology.
    N Z Med J; 1991 Oct; 104(922):438-40. PubMed ID: 1923103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients.
    Isidori A; Bonifazi F; Visani G; Gherlinzoni F; Baccarani M; Lemoli RM
    Haematologica; 2005 Jan; 90(1):139-41. PubMed ID: 15642686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis.
    Fagioli F; Bacigalupo A; Frassoni F; Van Lint MT; Occhini D; Gualandi F; Lamparelli T; Clavio M; Vitale V; Sogno G
    Bone Marrow Transplant; 1994 Mar; 13(3):247-52. PubMed ID: 8199567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.
    Mollee P; Gupta V; Song K; Reddy V; Califaretti N; Tsang R; Crump M; Keating A
    Bone Marrow Transplant; 2004 Jun; 33(12):1201-8. PubMed ID: 15094745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
    Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD
    J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
    Koistinen P; Räty R; Itälä M; Jantunen E; Koivunen E; Nousiainen T; Pelliniemi TT; Remes K; Ruutu T; Savolainen ER; Siitonen T; Silvennoinen R; Volin L; Elonen E;
    Eur J Haematol; 2007 Jun; 78(6):477-86. PubMed ID: 17391337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype.
    Damiani D; Tiribelli M; Raspadori D; Michelutti A; Gozzetti A; Calistri E; Candoni A; Chiarvesio A; Lenoci M; Russo D; Fanin R
    Hematol Oncol; 2007 Mar; 25(1):38-43. PubMed ID: 17200981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethnicity and prognosis in acute myeloid leukemia.
    Alcalai R; Ben-Yehuda D; Ronen I; Paltiel O
    Am J Hematol; 2003 Feb; 72(2):127-34. PubMed ID: 12555217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia.
    Baz R; Rodriguez C; Fu AZ; Jawde RA; Kalaycio M; Advani A; Sobecks R; Sekeres MA
    Cancer; 2007 Oct; 110(8):1752-9. PubMed ID: 17724726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
    Breems DA; Boogaerts MA; Dekker AW; Van Putten WL; Sonneveld P; Huijgens PC; Van der Lelie J; Vellenga E; Gratwohl A; Verhoef GE; Verdonck LF; Löwenberg B
    Br J Haematol; 2005 Jan; 128(1):59-65. PubMed ID: 15606550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
    Sousa AB; Fernandes JP; Costa I; Ferreira G; Nunes O; Ribeiro P; Neves A; Cruz E; Aveiro F; Rodrigues AS; Bernardo M; Conduto A; Gonçalves AJ; Monteiro A; Sousa M; Soares VH; Veiga J; Gouveia J
    Hematol Cell Ther; 1998 Apr; 40(2):63-6. PubMed ID: 9615248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.